FDA Proposes New Guidelines To Make Some Medical Devices Safer

Federal health officials have issued a new draft guidance to improve the safety and availability of medical devices used to treat serious and potentially life-threatening diseases or conditions.

The U.S. Food and Drug Administration (FDA) issued a draft guidance for the Safer Technologies Program for Medical Devices this month, which would fast-track the pre-market approval process for medical devices used to treat serious conditions not eligible under the Breakthrough Device Program.

Officials said the Safer Technologies Program (STeP) initiative is intended to help patients have more timely access to medical devices and device-led combination products by expanding their development, assessment, and review.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Medical devices qualified under the voluntary program will include those reasonably expected to significantly improve the safety of currently available treatments for diagnostics targeting underlying diseases or conditions associated with mortality.

The guidance states the statutory standards for premarket approval of these medical devices will be maintained, however the agency will be providing additional resources to help finalize products for market and patient use.

Similar to the Breakthrough Device Program which was created by the FDA to give patients more timely access to devices being developed to effectively treat or diagnosis life-threatening or irreversibly debilitating diseases or conditions, STeP will be offering a similar fast-track program for medical devices that do not qualify for the Breakthrough Device Program.

The program will offer manufacturers an opportunity to interact with the FDA’s experts through several different program options to efficiently address topics that will be addressed during the premarket review phases. These qualifying devices are also granted a prioritized review after being submitted for market approval to the FDA.

Often, medical devices can be held in the pre-market approval process while the FDA evaluates and ensures the safety for public use. Revisions of devices once ruled upon by the FDA can also cause significant delays in devices entering the market for medical use. The FDA claims that by allowing manufacturers a timely means of communication with FDA regulatory officials, devices that could save lives may be able to reach the hands of healthcare professionals and patients faster.

The FDA is accepting written documents to Docket Number FDA-2019-D-4048 until November 18, which can be sent to :

Dockets Management

Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Meningioma Brain Tumors Risks May Have Been Ignored by Pfizer for Decades
Depo-Provera Meningioma Brain Tumors Risks May Have Been Ignored by Pfizer for Decades (Posted 2 days ago)

After decades of medical research and reported Depo-Provera side effects, Pfizer should have known that its birth control shot increases the risks of meningioma brain tumors, yet failed to warn women or the medical community.

Philadelphia Roundup Lawsuit Ends in Defense Verdict for Monsanto
Philadelphia Roundup Lawsuit Ends in Defense Verdict for Monsanto (Posted 2 days ago)

Bayer and Monsanto prevailed in a Roundup lawsuit that went to trial in Philadelphia this week, after a jury found that exposure to the herbicide did not cause a man to develop non-Hodgkin's lymphoma.